328 related articles for article (PubMed ID: 19577961)
21. Association of soluble markers with various stages and major events of atherosclerosis.
Wu JT; Wu LL
Ann Clin Lab Sci; 2005; 35(3):240-50. PubMed ID: 16081579
[TBL] [Abstract][Full Text] [Related]
22. Value of CRP in coronary risk determination.
Mehta JL; Sukhija R; Romeo F; Sepulveda JL
Indian Heart J; 2007; 59(2):173-7. PubMed ID: 19122252
[TBL] [Abstract][Full Text] [Related]
23. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease.
Hurks R; Peeters W; Derksen WJ; Hellings WE; Hoefer IE; Moll FL; de Kleijn DP; Pasterkamp G
Thromb Haemost; 2009 Jan; 101(1):48-54. PubMed ID: 19132188
[TBL] [Abstract][Full Text] [Related]
24. [What are the biomarkers of atherosclerosis and cardiovascular risk?].
Riesen WF
Rev Med Suisse; 2008 Mar; 4(148):636-8, 640-3. PubMed ID: 18459658
[TBL] [Abstract][Full Text] [Related]
25. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
Koenig W
Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers of atherosclerotic plaque instability and rupture.
Koenig W; Khuseyinova N
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):15-26. PubMed ID: 17082488
[TBL] [Abstract][Full Text] [Related]
27. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
Zhao L; Jin W; Rader D; Packard C; Feuerstein G
Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
[TBL] [Abstract][Full Text] [Related]
28. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: pro-inflammatory effect on atherosclerosis.
Guo F; Liu J; Wang C; Liu N; Lu P
Biochem Biophys Res Commun; 2009 Dec; 390(3):942-6. PubMed ID: 19852936
[TBL] [Abstract][Full Text] [Related]
29. [Atherosclerosis (hypertension)].
Ai M
Nihon Rinsho; 2012 May; 70(5):840-5. PubMed ID: 22620010
[TBL] [Abstract][Full Text] [Related]
30. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
31. [The pro-inflammatory role of cytokines in the mechanism of atherosclerosis].
Correale M; Brunetti ND; Di Biase M
G Ital Cardiol (Rome); 2006 Sep; 7(9):594-603. PubMed ID: 17128781
[TBL] [Abstract][Full Text] [Related]
32. The vulnerable patient: refocusing on the plaque?
Eijgelaar WJ; Heeneman S; Daemen MJ
Thromb Haemost; 2009 Aug; 102(2):231-9. PubMed ID: 19652873
[TBL] [Abstract][Full Text] [Related]
33. The role of biomarkers and genetics in peripheral arterial disease.
McDermott MM; Lloyd-Jones DM
J Am Coll Cardiol; 2009 Sep; 54(14):1228-37. PubMed ID: 19778662
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers, atherosclerosis and cardiovascular events.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):619-22. PubMed ID: 18510479
[TBL] [Abstract][Full Text] [Related]
35. Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome.
Rizvi AA
Chin Med J (Engl); 2007 Nov; 120(21):1918-24. PubMed ID: 18067768
[No Abstract] [Full Text] [Related]
36. Hot and bothered: C-reactive protein, inflammation and atherosclerosis.
Wierzbicki AS
Int J Clin Pract; 2009 Nov; 63(11):1550-3. PubMed ID: 19832810
[No Abstract] [Full Text] [Related]
37. [Fibrinogen--acute phase protein as a marker of immunological process as atherosclerosis].
Rajtari R; Kloch M; Kiec-Wilk B; Kolasińska-Kloch W
Folia Med Cracov; 2005; 46(1-2):21-32. PubMed ID: 17037285
[TBL] [Abstract][Full Text] [Related]
38. [C-reactive protein and risk of ischaemic vascular and cerebrovascular disease--secondary publication].
Zacho J; Tybjaerg-Hansen A; Jensen JS; Grande P; Sillesen H; Nordestgaard BG
Ugeskr Laeger; 2009 May; 171(21):1751-5. PubMed ID: 19492468
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome.
LeLeiko RM; Vaccari CS; Sola S; Merchant N; Nagamia SH; Thoenes M; Khan BV
Am J Cardiol; 2009 Sep; 104(5):638-43. PubMed ID: 19699337
[TBL] [Abstract][Full Text] [Related]
40. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
